anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diverticulitis in a solitary transverse colon diverticulum is uncommon, with only a handful of cases documented in the literature. There are various clinical manifestations of the disease, which make clinical and radiological diagnosis rather challenging. Herein, we present a case of a premenopausal female patient in her late 40s who presented to the emergency department, complaining of right lower quadrant abdominal pain, nausea, anorexia and fever. Following clinical, biochemical and radiological tests, the patient was prepared for surgical operation, with the presumed diagnosis of acute appendicitis. An appendicectomy was planned via a McBurney incision. Notably, no inflammation of the appendix was discovered. However, on further exploration, an inflammatory mass was identified in the transverse colon, which was subsequently excised and sent for histological examination. The histology results confirmed the presence of a ruptured solitary transverse colon diverticulum, accompanied by an adjacent mesenteric abscess. The patient's postoperative recovery was uneventful.
For intravenous injection or intravenous infusion after reconstitution only.

  * Inspect the reconstituted FEIBA solution visually for particulate matter and discoloration prior to administration. The appearance of the solution should be colorless to slightly yellowish. Do not use if particulate matter or discoloration is observed.
  * Flush venous access lines with isotonic saline prior to and after infusion of FEIBA. Do not administer in the same tubing or container with other medicinal products.
  * Use plastic Luer lock syringes because protein such as FEIBA tends to stick to the surface of all-glass syringes.
    1. Remove the blue protective cap from the BAXJECT II Hi-Flow device. Tightly connect the syringe to the BAXJECT II Hi-Flow device (DO NOT DRAW AIR INTO THE SYRINGE) by turning the syringe in clockwise direction until stop position. Use of a Luer lock syringe is highly recommended to ensure a tight connection between the syringe and the BAXJECT II Hi-Flow device (Fig. E).
    2. Invert the system so that the dissolved FEIBA product is on top. Draw the dissolved product carefully into the syringe by pulling the plunger back slowly to avoid foaming (Fig. F).
    3. Ensure that the tight connection between the BAXJECT II Hi-Flow device and the syringe is maintained.
    4. Disconnect the syringe.
    5. Attach a suitable needle and inject or infuse intravenously at a rate that does not exceed 10 units per kg of body weight per minute. A syringe pump may be used to control the rate of administration. For a patient with a body weight of 75 kg, this corresponds to an infusion rate up to 15 mL per minute.
PURPOSE:To improve the precision in automatic diagnosis by calculating the correction value by verifying the difference of subjectivity between an observer and an expert before estimation and correcting the fuzzy scale inputted by the observer on the basis of the correction value and estimating the fuzzy scale. CONSTITUTION:A gestalt correction part 5 reads out the pattern corresponding to the observation items from a pattern memory part 8 and displays the result to an inspector, who inputs the observation value attached to the pattern, and stores the value into a user monitoring memory U. The difference between the expert monitoring value which is read out from an expert monitoring value memory E by an expert and the user observation value read out from a user observation memory U is calculated, and the result is sent as the correction value for the subjectivity of both into a fuzzy scale correction part 6. The correction part 6 corrects the fuzzy scale inputted by the inspector on the basis of the above-described correction value and sends the corrected value into an estimation part 7. The estimation part 7 reads out the membership function corresponding to the fuzzy scale after correction, and estimates the result of the image diagnosis. Accordingly, even if a difference exists between the subjectivity of the observer and the expert, the observer can obtain the equal diagnostic result comparable to that by the expert.
Women with thin endometrium/endometrial atrophy and/or Asherman's syndrome with fertility problems and reproductive desires, desires that could be achieved by their participation in the present study. A total of 15 patients will be included; all of them will receive the investigational treatment as well as estrogen therapy.
The research is the first evaluation of an unsupervised HIV self-testing strategy in Tanzania focusing on networks of heterosexual men. The reasons for focusing on heterosexual men is because heterosexual contact is the primary mode of HIV transmission in Tanzania and data from our previous trial indicate that 97% of the male camp members are heterosexual. Moreover it will be the first intervention to engage male peer leaders to promote HIV self-testing in their social networks in Tanzania. We will build on previous work our research team has conducted to identify 'camps' or local venues where young men socialize with elected leaders and members pay membership dues. Our previous intervention has proven successful to recruit and train leaders from camps to serve as community health leaders in their respective camps, with the goal of changing social norms related to HIV and gender-based violence. A novel approach to the proposed research is that we will leverage the work we have conducted within camps with social networks of men to test the acceptability and feasibility of oral fluid-based HIV self-testing and confirmatory blood-based HIV testing within existing networks of men that we know we can access through stable social venues. We will recruit male camp leaders to train them about HIV self-testing and instruct them to return to their camps and engage their male peers by informing them about HIV self-testing for prior to our research team offering participants the opportunity to self-test.
PURPOSE: A composition containing PPAR-alpha activating agent is provided to promote skin differentiation, to strengthen skin barrier function, and to treat atopic dermatitis. CONSTITUTION: A composition for PPAR-alpha contains linoleoyl-glycerol of chemical formula 1 as an active ingredient. A composition for treating or preventing atopic dermatitis contains 3-linoleoyl-glycerol of chemical formula 1 as an active ingredient. The 3-linoleoyl-glycerol is isolated from Zanthoxylum bungeanum Maxim. The compositions contain 0.000001-10 weight% of 3-linoleoyl-glycerol. The compositions are used in the form of skin, lotion, cream, foundation, essence, gel, pack, foam cleansing, soap, or ointment.
The quick-release preparation for targeted therapy of hyperlipidemic acute pancreatitis consists of a basic solution and drug-loaded microvesicles. Of base solutionsThe components comprise sodium alginate and trehalose, wherein the mass ratio of the sodium alginate to the trehalose is 1: 10. The drug-loaded microvesicles consist of nitric oxide microvesicles carrying insulin. The nitric oxide microvesicle is formed by wrapping nitrogen monoxide by using hydrogenated soybean phospholipid and heparin-poloxamer as vesicle membrane materials, and the mass ratio of the hydrogenated soybean phospholipid to the heparin-poloxamer is 1: 2. The molar mass of insulin is equal to that of heparin-poloxamer, and the insulin adheres to the surface of nitric oxide microbubbles. The particle size range of the drug-carrying microvesicle is 2-5 μm, and the concentration of the drug-carrying microvesicle in the quick-release preparation is 1 multiplied by 10 6 ～5×10 6 one/mL. The quick-release preparation disclosed by the invention realizes accurate positioning and targeted delivery of a pancreas part by an ultrasonic mediated technology after intravenous injection, and is used for treating hyperlipidemic acute pancreatitis.
Rural counties, particularly in Appalachia, are battling fast-growing outbreaks of HIV and have been labeled by the CDC as vulnerable to growing transmission rates due to widespread injection drug use. One of the most promising mechanisms for reducing HIV transmission in these communities is the use of buprenorphine, which treats opioid use disorder and also reduces behaviors that increase HIV risk. Despite the potential benefit of buprenorphine, health care professionals (HCPs) in rural areas of the United States are much less likely to have received the training and federal waiver necessary to prescribe this medication. Stigma toward patients who use drugs is an accepted barrier to substance use treatment, but it also impacts health care professionals, especially rural primary care prescribers such as physicians, nurse practitioners, and physicians assistants who are on the front lines of the opioid crisis. The investigators have shown in previous studies that stigma is a primary reason why fewer rural health care professionals are willing to work with patients with OUD. Stigma and negative attitudes toward patients with OUD, fortunately, are modifiable but require training interventions that are both effective and feasible to implement in rural practice settings. Previous interventions have been used with health care professionals successfully to reduce stigma, but they have not been tailored for medications for opioid use, such as buprenorphine, or for the rural primary care setting. The study team proposes to adapt an existing brief stigma-reduction training intervention to the rural primary care setting to increase buprenorphine prescribing and implement a randomized, pilot study to assess feasibility and acceptability among rural primary care providers. Our specific aims are to: 1) Examine HCP knowledge and attitudes about OUD to understand their reluctance to prescribe MOUD and manage patients with OUD. 2) Develop a prototype narrative-based stigma reduction intervention and tailor it to the rural primary care setting using HCP feedback and 3) Assess the feasibility and acceptability of a stigma-reduction intervention in a pilot study in a diverse group of rural HCPs across 6 primary care clinics. The primary pilot trial outcomes are feasibility, acceptability, appropriateness, and adoption, measured among a cohort of HCPs who do not currently prescribe buprenorphine at full capacity. The investigators will also measure additional stigma outcomes such as attitudes towards patients with OUD and harm reduction. The invesstigators will use in-depth interviews to further assess perceptions of the intervention and finalize it for use in a follow-up cluster randomized controlled trial. This developmental trial will produce a brief stigma reduction training intervention that is acceptable and feasible to implement in rural primary care clinics. The long-term goal is to establish a brief stigma-reduction training intervention that is modifiable for different practice settings and effective at increasing buprenorphine prescribing in underserved communities.
PURPOSE: A composition containing alpha-viniferin from Carex humilis Leyss. as a main component is provided. The alpha-viniferin inhibits COX-2 activity and TNF release at the same time, but not COX-1 and is thus effectively used in treatment of various inflammatory disorders associated with COX-2 and TNF, containing arthritis. CONSTITUTION: A pharmaceutical composition for prevention and treatment of arthritis contains alpha-viniferin induced from Carex humilis Leyss. and a pharmaceutically acceptable carrier. The composition is formulated into an oral formulation such as tablets or capsules, an external formulation, a suppository or a sterile injectable solution. The effective dose of the composition is 2 to 20mg/kg body weight.
The invention relates to a traditional Chinese medicine sustained release preparation. The weight parts of the components are 2-20 parts of dogwood total alkaloids, 1-5 parts of release retarder, 0-5 parts of release promoter, 1-5 parts of bleaching auxiliary and 0.01-2 parts of pharmaceutic adjuvant. Coptis chinensis is concentrated by using water, acid water or ethanol as solvent extract, then separated and purified by macroporous adsorptive resins to prepare the coptis chinensis total alkaloids with a content of over 50%. Evodiae extract solution is concentrated and alkalized by acetidin extraction to obtain 50% content of evodiae total alkaloids. Compared with conventional preparations, the sustained release preparation in the invention can better keep stable blood drug level in the human body, thus avoiding severe adverse effects resulting from large flunctuation of blood drug level. The preparation is easy to take, improving compliance of the patients.
ETHNOPHARMACOLOGICAL RELEVANCE: Sanchen powder is a traditional Tibetan medicine comprising Bambusae Concretio Silicea, Carthami Flos, and Bovis Calculus Artifactus. Bambusae Concretio Silicea is the dried mass of secreted fluid in the stalks of Gramineae plants such as Bambusa textilis McClure or Schizostachyum chinense Rendle. Carthami Flos is the dried flower of Carthamus tinctorius L. in the Compositae plant. Bovis Calculus Artifactus is made from ox bile powder, cholic acid, hyodeoxycholic acid, taurine, bilirubin, cholesterol, and trace elements. Research has evidenced the antibacterial efficacy of Sanchen powder, albeit its active constituents for this effect are yet to be established.
AIM OF THE STUDY: To investigate effective compounds, potential targets, and molecular mechanism of Sanchen powder for its antibacterial properties by using network pharmacology combined with in vitro validation, with the aims of observing the action of effective compounds in Sanchen powder and exploring new therapeutic strategies for antibacterial.
MATERIALS AND METHODS: In this study, UPLC-Q-TOF-MS was utilized to identify the chemical composition in Sanchen powder and its blood-borne chemical ingredients post-oral intake. A network pharmacology analysis was used to establish the chemical compound in the blood following oral administration-target-disease network. The study aimed to identify antibacterial active ingredients, which were then subjected to molecular docking and pharmacodynamic experiments to verify their efficacy.
RESULTS: The findings demonstrate that following oral administration, the blood contains seven key components of Sanchen powder, including bilirubin, glycochenodeoxycholic acid, glycocholic acid, taurocholic acid, phenylalanine, safflomin A, and tryptophan. Additionally, the network pharmacology and molecular docking study results indicate the potential antibacterial effects of bilirubin, glycocholic acid, and glycochenodeoxycholic acid. In vitro antibacterial experiments revealed that bilirubin, glycocholic acid, and glycochenodeoxycholic acid could restrict the growth of the Staphylococcus aureus cell membrane at a certain concentration. Moreover, they exhibited antibacterial effects on Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, and Escherichia coli.
CONCLUSIONS: Bilirubin, glycocholic acid, and glycochenodeoxycholic acid could be effective therapeutic ingredients for the antibacterial effects of Sanchen powder. These results offer a foundation for further clinical application and research on the antibacterial effect of Sanchen powder, a Traditional Tibetan Medicine.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and can be used to treat pancreatic cancer in a human patient. To this end, the patient is administered an effective amount of liposomal irinotecan, 5-fluorouracil (5-FU) and leucovorin. Method includes at least one cycle, wherein the cycle is a 2 week period. For each cycle, liposomal irinotecan is administered to patients not homozygous for the UGT1A1*28 allele, on day 1 of each cycle at a dose of 80 mg/m, and patients that are homozygous for the UGT1A1*28 allele, on day 1 of cycle 1 at a dose of 60 mg/mand on day 1 of each subsequent cycle at a dose of 60 mg/mor 80 mg/m. 5-Fluorouracil is administered at a dose of 2400 mg/m. Leucovorin is administered at a dose of 200 mg/m(l-form) or 400 mg/m(l+d-racemic form). Also disclosed is the use of the liposomal irinotecan composition, and a kit for treating pancreatic cancer in a human patient.EFFECT: group of inventions provides treatment of pancreatic cancer in a human patient not homozygous or homozygous for the UGT1A1*28 allele.23 cl, 9 tbl, 7 dwg, 7 ex
Pregnancy Category C: Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity. The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180, and 100 times the human dose.

Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning. No effects were observed at 60 times the human dose. When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability.

There are no adequate and well controlled studies in pregnant women. Clotrimazole troches should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The external urethral sphincter (EUS) is crucial in urinary continence development. Understanding the morphological features of the EUS in female rats after vaginal distention (VD), using a model of birth trauma, would aid in evaluating its functional and metabolic properties. Our recent study demonstrated that the EUS in female rats expresses one slow (type 1) and two fast (types 2A and 2B) myosin heavy chain (MHC) isoforms. Our preliminary experiment revealed that type 2B isoform expression was markedly reduced in the EUS 4 weeks after VD. Here, we aimed to examine the expression patterns of these three types of MHC isoforms, and an embryonic MHC, a marker of regeneration fibers, in the EUS of rats 3 days and 1, 2, and 8 weeks after VD using immunofluorescence staining. Hence, type 2B fibers were selectively damaged early in post-VD and did not recover fully later. Muscle regeneration in the sphincter peaked 1 week after trauma using a marker of immature fibers, embryonic myosin heavy chain. Electron microscopy revealed that the EUS of female rats was composed of mitochondria-rich muscle fibers. Myoblasts or immature muscle fibers were discovered in the sphincter layer 1 week after trauma. These results suggest that myogenesis after VD may not contribute to restoring normal fiber composition in a female rat's EUS.
Detailed Description: The study was conducted in 2 parts. Part I: was conducted using a cross-sectional design approach to explore the relationship between cognitive function and autonomic function, brain function, inflammation and oxidative stress, vascular function, fitness levels, cardiorespiratory endurance and lipid metabolism. Multiple linear regression was used to analyse the multiple linear relationships between changes in cognitive function and the above influences. Multiple logistic regression analysis was also used to analyse which of the above risk factors might be independent predictors of cognitive decline. Therefore, a combination of both regression analyses was used to further explore the multiple linear relationships between cognitive function and the aforementioned influencing factors, providing a viable causal and theoretical basis for the next exercise intervention.

The second part of the study is to test the viability of the vascular function theory. The "vascular function theory" refers to the use of exercise to improve aerobic capacity, improve blood circulation to the heart, and improve cerebrovascular function, which in turn improves cognitive function. Based on the above hypothesis, this study aims to investigate the possible effects of 12 weeks of different types of exercise on cognitive decline in post-menopausal women with HTN, and to lay the theoretical and practical foundation for the extension of the exercise intervention to other ages and populations.
Cytarabine Injection, an antineoplastic, is a sterile isotonic solution for intravenous and subcutaneous use, which contains no preservative and is available in 20 mg/mL (1000 mg/50 mL) Pharmacy Bulk Package.

A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.

Each mL contains 20 mg Cytarabine, USP and the following inactive ingredients: sodium chloride 0.68% and Water for Injection q.s. When necessary, the pH is adjusted with hydrochloric acid and/or sodium hydroxide to a target pH of 7.4. Each vial contains approximately 5.82 mEq sodium.

Cytarabine is chemically 4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone. The structural formula is:

Cytarabine is an odorless, white to off-white, crystalline powder which is freely soluble in water and slightly soluble in alcohol and in chloroform.
PURPOSE:To provide a highly safe antioxidant composition free from problems in terms of toxicity, usable as a raw material for foods, cosmetics, or medicines, formulated with a combination of a tocopherol of natural origin and sphingosin. CONSTITUTION:This antioxidant composition formulated with a combination of pref. each 0.001-1wt.% of (A) a tocopherol (pref. delta-tocopherol) and (B) a sphingosin (e.g. extracted from bovine brain). This combination potentiates the antioxidizing power synergistically. Incorporation of this composition in cosmetics formulated with fatty oil can prevent the fatty oil from oxidation. This composition can be used in biological systems to prevent the systems from lipid peroxidation.
The invention relates to a 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide-containing inhalant and a preparation method thereof. 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide is called as an international nonproprietary name roflumilast. The roflumilast dry powder inhalant utilizes roflumilast as a medicinal active component and roflumilast and pharmaceutically acceptable accessory materials are mixed into the roflumilast dry powder inhalant. The roflumilast dry powder inhalant is applied through nasal cavity or nasal cavity. The preparation method has simple processes, is suitable for large-scale production and has the characteristics of simple administration, fast action and convenient carrying. The roflumilast dry powder inhalant can effectively treat bronchial asthma and chronic obstructive pneumonia.
Fragile X Syndrome is a genetically determined neurological disorder in which affected individuals are intellectually handicapped to varying degrees and display a variety of associated psychiatric symptoms. Clinically, Fragile X Syndrome is characterized by intellectual handicap, hyperactivity and attentional problems, autism spectrum symptoms, emotional lability and epilepsy. The epilepsy seen in Fragile X Syndrome is most commonly present in childhood, but then gradually remits towards adulthood. Physical features such as prominent ears and jaw, and hyper-extensibility of joints are frequently present but are not diagnostic. Intellectual handicap is the most common feature defining the phenotype. Treatment for the disorder is symptomatic - focusing on the management of symptoms - and supportive, requiring a multidisciplinary approach.

This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment.